Valuation : NanoVibronix Inc

Market Cap 3.72M 3.2M 3.01M 2.75M 5.15M 351M 5.16M 35.61M 13.82M 180M 13.98M 13.67M 581M P/E 2024 *
-
P/E 2025 -0.09x
Enterprise Value 696K 599K 563K 514K 962K 65.67M 965K 6.65M 2.58M 33.7M 2.61M 2.56M 109M EV / Sales 2024
0.62x
EV / Sales 2025 -0.2x
Free-Float
83.59%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 57 2025-06-03
Director of Finance/CFO 53 2025-12-17
Chief Tech/Sci/R&D Officer 45 2024-05-31
Director TitleAgeSince
Director/Board Member 57 2025-02-13
Chairman 76 2026-07-13
Director/Board Member 48 2025-12-04
Change 5-day change 1-year change 3-year change Capi.($)
+5.56%-35.71% - - 3.72M
+3.33%+2.86%-23.88%+1.56% 13.22B
-2.36%-4.13%+10.60%+8.67% 4.23B
+3.96%+3.48%-37.52%-54.42% 1.27B
-1.36%-1.81%-36.41%-40.71% 1.14B
-3.63%-4.16%+15.92%+76.05% 1.07B
-1.80%-0.34% - - 1.03B
-0.50%-2.68%-37.21% - 1.02B
-3.35%-6.37%+25.67%+100.16% 503M
+0.34%+1.01%+67.32% - 300M
Average +0.02%-1.88%-1.94%+15.22% 2.64B
Weighted average by Cap. +1.25%+0.30%-15.29%+3.42%

Financials

2024 2025
Net sales 2.56M 2.2M 2.07M 1.89M 3.54M 242M 3.55M 24.47M 9.5M 124M 9.61M 9.4M 399M 2.55M 2.2M 2.07M 1.89M 3.53M 241M 3.54M 24.42M 9.48M 124M 9.59M 9.38M 398M
Net income -3.7M -3.19M -3M -2.74M -5.13M -350M -5.14M -35.45M -13.75M -179M -13.91M -13.61M -578M -18.18M -15.65M -14.72M -13.45M -25.16M -1.72B -25.23M -174M -67.51M -881M -68.29M -66.8M -2.84B
Net Debt -636K -547K -515K -470K -880K -60.05M -882K -6.08M -2.36M -30.81M -2.39M -2.34M -99.25M -3.03M -2.6M -2.45M -2.24M -4.19M -286M -4.2M -28.96M -11.24M -147M -11.37M -11.12M -472M
Logo NanoVibronix Inc
ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.
Employees
-